AdaptHealth Slashes Guidance After $133.9M Q2 Loss, Stock Plunges 26%
AHCO is trading near its 52-week low of $8.505 (7.1% below the low).
Summary
AdaptHealth swung to a $133.9M Q2 loss, missing estimates by a wide margin, and slashed full-year revenue guidance by $600M at the midpoint. The loss was driven by a $144.2M goodwill impairment, while revenue of $740.3M fell well short of the $846.8M consensus. Management cited an unexpected manufacturer price increase and margin pressure from the pending diabetes business divestiture. This follows the July 20 announcement of the $235M sale to Cardinal Health and a July 2 cybersecurity incident disclosure. The stock is down 26% pre-market, trading near its 52-week low. The magnitude of the guidance cut and the surprise loss suggest deeper operational challenges beyond the one-time impairment.
At the time of this announcement, AHCO was trading at $7.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $8.51 to $13.43. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.